Navigation Links
Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
Date:11/22/2011

BOSTON, Nov. 22, 2011 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) is pleased to announce that it finished the 3rd Quarter with a Net Profit of $73,895.  Solos Endoscopy has consummated agreements which resulted in the Forgiveness of debt of $299,082 for the Three Months period ending September 30, 2011.  The signed settlement agreement and new consulting agreement result in a reduction of ongoing expenses by approximately $40,000 per quarter.

Solos Endoscopy posted its financial statements for period ended September 30, 2011.  While the Company saw a modest decrease in sales over the three month period, the Net Profit is a result of Management's cost cutting and debt reduction efforts.  Management is extremely pleased with the increase in demand for its new MammoView® instrument line.

The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.

"Solos management has worked extremely hard to position the Company for future success.  This is represented by our tireless efforts to work with our creditors, while remaining focused on future product development. We have allocated significant resources to the development of the MammoView® instrument line.  The fact that we have taken this tremendous product from concept phase to sales in dozens of hospitals across the Country is truly amazing.  I'd like to thank the shareholders for all their continued support," stated Bob Segersten, President of Solos Endoscopy, Inc.

Please visit http://www.otcmarkets.com/stock/SNDY/financials for more information.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact: Amanda Segersten, rsegersten@solosendoscopy.com


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
2. Solos Endoscopy Goes Google
3. Solos Endoscopy Finishes the 3rd Quarter Strong
4. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
5. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
6. Solos Endoscopy Reports 32% Increase in Breast Endoscopy Sales
7. Solos Endoscopy to Reduce Debt by Over $620,000
8. Solos Endoscopys MammoView® System Proves Crucial to Early Breast Cancer Detection
9. Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction
10. Solos Endoscopy, Inc. To Launch New Corporate Website
11. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):